Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Consensus Rating of “Hold” by Brokerages

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) have earned an average rating of “Hold” from the nine brokerages that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $44.1429.

Several analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday. Wedbush restated an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research note on Monday, December 22nd. HC Wainwright reaffirmed a “buy” rating and set a $44.00 target price on shares of Zenas BioPharma in a report on Tuesday, March 17th. Citigroup dropped their target price on Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Finally, Morgan Stanley raised their price target on shares of Zenas BioPharma from $19.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 17th.

Insider Transactions at Zenas BioPharma

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. bought 57,000 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was bought at an average cost of $17.96 per share, for a total transaction of $1,023,720.00. Following the completion of the transaction, the chief executive officer directly owned 423,155 shares of the company’s stock, valued at approximately $7,599,863.80. This trade represents a 15.57% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Patricia L. Allen purchased 4,160 shares of the stock in a transaction on Friday, February 13th. The stock was acquired at an average cost of $26.36 per share, for a total transaction of $109,657.60. Following the completion of the acquisition, the director owned 19,860 shares of the company’s stock, valued at $523,509.60. The trade was a 26.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 202,845 shares of company stock worth $3,747,185 over the last 90 days. 22.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zenas BioPharma

A number of institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. raised its position in Zenas BioPharma by 41.2% during the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock valued at $89,000 after acquiring an additional 2,679 shares in the last quarter. Geode Capital Management LLC boosted its position in Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after purchasing an additional 16,461 shares in the last quarter. Intech Investment Management LLC boosted its position in Zenas BioPharma by 13.9% in the 2nd quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock worth $128,000 after purchasing an additional 1,607 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after purchasing an additional 8,207 shares during the period. Finally, Federated Hermes Inc. increased its holdings in shares of Zenas BioPharma by 60.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after purchasing an additional 703,838 shares in the last quarter.

Zenas BioPharma Trading Up 0.1%

NASDAQ ZBIO opened at $18.23 on Thursday. The company has a fifty day simple moving average of $23.14 and a two-hundred day simple moving average of $27.32. The stock has a market cap of $1.05 billion, a P/E ratio of -2.33 and a beta of -1.96. Zenas BioPharma has a 12-month low of $6.11 and a 12-month high of $44.60. The company has a current ratio of 5.61, a quick ratio of 5.61 and a debt-to-equity ratio of 0.32.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings data on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.